Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Shire    SHP   JE00B2QKY057

SHIRE (SHP)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 11/15 05:35:09 pm
4621 GBp   +0.46%
11/15SHIRE : Form 8.3 - Takeda Pharmaceutical Company Ltd
PU
11/15SHIRE : Form 8 (DD) - Citibank NA Switzerland
PU
11/15SHIRE : Form 8 (DD) Citibank NA London
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweetsMarketScreener Strategies

Shire : Form 8.3 -

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/09/2018 | 04:14pm CET

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the 'Code')

1. KEY INFORMATION

(a) Full name of discloser:

T. ROWE PRICE ASSOCIATES, INC. & ITS AFFILIATES

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

SHIRE PLC

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

08 November 2018

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state 'N/A'

YES

If YES, specify which:

TAKEDA PHARMACEUTICAL COMPANY LIMITED

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

Ordinary Shares

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

9,502,218

1.0

(2) Cash-settled derivatives:

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

TOTAL:

9,502,218

1.0

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors' and other employee options)

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

ADR

Ordinary Shares

Sale

Purchase

Sales

100

255

789

180.980 USD

45.601 GBP

45.940 GBP

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state 'none'

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state 'none'

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:

09 November 2018

Contact name:

Gary Greb

Telephone number:

410-345-2527

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

Disclaimer

Shire plc published this content on 09 November 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 09 November 2018 15:13:02 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SHIRE
11/15SHIRE : Form 8.3 - Takeda Pharmaceutical Company Ltd
PU
11/15SHIRE : Form 8 (DD) - Citibank NA Switzerland
PU
11/15SHIRE : Form 8 (DD) Citibank NA London
PU
11/15SHIRE : Form 8 (DD) - Citibank NA Jersey
PU
11/15SHIRE : Form 8.5 (EPT/NON-RI)- Shire Plc
PU
11/15TAKEDA PHARMACEUTICAL : Announces Publication of Circular and Notice of Extraord..
AQ
11/15SHIRE : Form 8.5 (EPT/RI)- Shire plc
PU
11/14SHIRE PLC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/14SHIRE : Form 8.5 (EPT/RI)- Shire plc AMENDMENT
PU
11/14FORM 8.3 - THE VANGUARD GROUP, INC. : Shire plc
PU
More news
News from SeekingAlpha
11/15Top Merger Stocks Held By Fund Managers, Mid-Q4 2018 
11/14Tracking Seth Klarman's Baupost Group Holdings - Q3 2018 Update 
11/14MERGER UPDATES : B.Riley/magicJack Brought 7%+ In A Month. A Few New Deals. 
11/13Express Scripts launches new formulary aimed at reducing drug costs 
11/13Merger Arbitrage Mondays - November 12, 2018 
Financials ($)
Sales 2018 15 504 M
EBIT 2018 5 763 M
Net income 2018 2 667 M
Debt 2018 14 704 M
Yield 2018 0,59%
P/E ratio 2018 19,06
P/E ratio 2019 16,01
EV / Sales 2018 4,48x
EV / Sales 2019 4,15x
Capitalization 54 740 M
Chart SHIRE
Duration : Period :
Shire Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHIRE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 65,0 $
Spread / Average Target 8,8%
EPS Revisions
Managers
NameTitle
Flemming Ornskov Chief Executive Officer
Susan Saltzbart Kilsby Non-Executive Chairman
Thomas J. W. Dittrich Chief Financial Officer & Director
Howard Mayer Chief Medical Officer
Matthew Walker Head-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
SHIRE18.49%54 740
JOHNSON & JOHNSON3.24%386 875
PFIZER18.47%248 878
NOVARTIS6.63%222 584
ROCHE HOLDING LTD.0.93%213 164
MERCK AND COMPANY31.67%192 662